Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > remember my words

<< Previous

Bullboard Posts

Next >>

Post by Layth1990on Feb 19, 2021 1:44pm

187 Views

Post# 32611284

remember my words

after feb 24 we will see climbing in sp, within a week or 2 we will sit between 7 and 7.5. i don't think any NR will be announced before feb 24 because that will push price up and the deal is 6cad/share.

let me tell you this, when a company buys 36m at 6 cad, those guys know the price will go up by catalysts. they already discussed the catalysts with antibe and their team evaluated the impact on sp. no one will invest 36m at 6 cad/share and 2 weeks ago the price was bellow 4cad/share.

Let that sink.

<< Previous

Bullboard Posts

Next >>

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains